Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

Future Oncol. 2016 Mar;12(5):637-45. doi: 10.2217/fon.16.2. Epub 2016 Feb 3.


Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma.

Materials & methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation.

Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years.

Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.

Keywords: SABR; SBRT; ablation; kidney cancer; patterns of practice; radiotherapy; stereotactic.

Publication types

  • Consensus Development Conference

MeSH terms

  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / surgery*
  • Clinical Trials, Phase I as Topic
  • Consensus
  • Disease Management
  • Expert Testimony
  • Follow-Up Studies
  • Health Care Surveys
  • Humans
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / surgery*
  • Neoplasm Staging
  • Patient Outcome Assessment
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Radiosurgery* / methods
  • Radiotherapy Dosage
  • Therapy, Computer-Assisted / methods